The traditional therapy for the advanced stage NSCLC is mainly systemic chemotherapy.1 After the epidermal growth factor receptor (EGFR) gene mutation‐driven NSCLC has been claimed, tyrosine kinase inhibitors (TKIs) have already replaced traditional chemotherapy as the standard first‐line therapy for advanced‐stage NSCLC patients with EGFR‐sensitive mutations.2, 3 Unlike those NSCLC patients with classical EGFR mutations (EGFRcm),2, 4, 5 the prevalence and TKIs response in EGFR uncommon mutation (EGFRum) NSCLC patients remain under study. This evidence concerns the gene EGFR and non-small cell lung carcinoma.